BACKGROUND AND PURPOSE: Vascular endothelial growth factor (VEGF) is an important determinant of microvascular permeability and angiogenesis and has been shown to be up-regulated during the late phase of radiation injury. The present prospective study was performed to evaluate the role of VEGF gene polymorphisms and haplotypes in the development of radiation-induced late side effects in prostate cancer patients. PATIENTS AND METHODS: The association of VEGF gene polymorphisms and haplotypes with high-grade late rectal or urinary toxicity (defined as late toxicity EORTC/RTOG ≥ 2) was analyzed using 493 prostate cancer patients from the Austrian PROCAGENE study treated with definitive radiotherapy. Seven candidate polymorphisms in the VEGF gene were selected and determined by 5'-nuclease (TaqMan) assays. RESULTS: Within a median follow-up time of 48 months, 42 patients (8.6%) developed high-grade late rectal and 47 patients (9.6%) urinary toxicity, respectively. In a Kaplan-Meier analysis, carriers of the VEGF -7C > T polymorphism were at increased risk of high-grade late rectal toxicity (p = 0.003) and in a multivariate analysis including clinical and dosimetric parameters as potential confounders the VEGF -7C > T polymorphism remained a significant predictor (HR = 2.8, 95% CI 1.349-5.813; p = 0.006). Furthermore, the ATTGT haplotype formed by five polymorphisms upstream of the coding sequence demonstrated a significant association with late rectal toxicity grade ≥ 2 (p = 0.001). No significant associations were found for the remaining polymorphisms and haplotypes. CONCLUSION: We conclude that genetic variants in the VEGF gene may influence the risk of high-grade late rectal toxicity after definitive radiotherapy for prostate cancer.
BACKGROUND AND PURPOSE:Vascular endothelial growth factor (VEGF) is an important determinant of microvascular permeability and angiogenesis and has been shown to be up-regulated during the late phase of radiation injury. The present prospective study was performed to evaluate the role of VEGF gene polymorphisms and haplotypes in the development of radiation-induced late side effects in prostate cancerpatients. PATIENTS AND METHODS: The association of VEGF gene polymorphisms and haplotypes with high-grade late rectal or urinary toxicity (defined as late toxicity EORTC/RTOG ≥ 2) was analyzed using 493 prostate cancerpatients from the Austrian PROCAGENE study treated with definitive radiotherapy. Seven candidate polymorphisms in the VEGF gene were selected and determined by 5'-nuclease (TaqMan) assays. RESULTS: Within a median follow-up time of 48 months, 42 patients (8.6%) developed high-grade late rectal and 47 patients (9.6%) urinary toxicity, respectively. In a Kaplan-Meier analysis, carriers of the VEGF -7C > T polymorphism were at increased risk of high-grade late rectal toxicity (p = 0.003) and in a multivariate analysis including clinical and dosimetric parameters as potential confounders the VEGF -7C > T polymorphism remained a significant predictor (HR = 2.8, 95% CI 1.349-5.813; p = 0.006). Furthermore, the ATTGT haplotype formed by five polymorphisms upstream of the coding sequence demonstrated a significant association with late rectal toxicity grade ≥ 2 (p = 0.001). No significant associations were found for the remaining polymorphisms and haplotypes. CONCLUSION: We conclude that genetic variants in the VEGF gene may influence the risk of high-grade late rectal toxicity after definitive radiotherapy for prostate cancer.
Authors: Sambasivarao Damaraju; David Murray; Jennifer Dufour; Diana Carandang; Sten Myrehaug; Gino Fallone; Colin Field; Russell Greiner; John Hanson; Carol E Cass; Matthew Parliament Journal: Clin Cancer Res Date: 2006-04-15 Impact factor: 12.531
Authors: Kim De Ruyck; Marc Van Eijkeren; Kathleen Claes; Rudy Morthier; Anne De Paepe; Anne Vral; Leo De Ridder; Hubert Thierens Journal: Int J Radiat Oncol Biol Phys Date: 2005-07-15 Impact factor: 7.038
Authors: A Schultz; L Lavie; I Hochberg; R Beyar; T Stone; K Skorecki; P Lavie; A Roguin; A P Levy Journal: Circulation Date: 1999-08-03 Impact factor: 29.690
Authors: Z Vujaskovic; M S Anscher; Q F Feng; Z N Rabbani; K Amin; T S Samulski; M W Dewhirst; Z A Haroon Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-15 Impact factor: 7.038
Authors: H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui Journal: Gut Date: 2003-09 Impact factor: 23.059
Authors: Einar K Rofstad; Jon-Vidar Gaustad; Tormod A M Egeland; Berit Mathiesen; Kanthi Galappathi Journal: Int J Cancer Date: 2010-10-01 Impact factor: 7.396
Authors: Joke Werbrouck; Kim De Ruyck; Fréderic Duprez; Liv Veldeman; Kathleen Claes; Marc Van Eijkeren; Tom Boterberg; Petra Willems; Anne Vral; Wilfried De Neve; Hubert Thierens Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-15 Impact factor: 7.038
Authors: Kimberly E Alexander; Suzanne Chambers; Amanda B Spurdle; Jyotsna Batra; Felicity Lose; Tracy A O'Mara; Robert A Gardiner; Joanne F Aitken; Judith A Clements; Mary-Anne Kedda; Monika Janda Journal: Qual Life Res Date: 2015-02-28 Impact factor: 4.147
Authors: V Strenger; H Lackner; R Mayer; P Sminia; P Sovinz; M Mokry; A Pilhatsch; M Benesch; W Schwinger; M Seidel; D Sperl; S Schmidt; C Urban Journal: Strahlenther Onkol Date: 2013-08-22 Impact factor: 3.621